Pavaki Capital Management, LLC
Pavaki Capital Management, LLC is an SEC-registered investment adviser that reports managing 1 hedge fund on Form ADV. It reports $410.1 million in regulatory assets under management. Its private funds, of all types, hold $410.1 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +0.1% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +0.1% from Q1 2026 to Q2 2026, compared with +9.5% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $410.1 millionForm ADV Item 5.F
- Gross assets of private funds
- $410.1 millionAll private fund types, Form ADV
- Hedge funds managed
- 11 private funds in total
- Employees
- 6Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 316395
- Latest Form ADV
- 08/06/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +10.5% | +14.8% |
| Q1 2026 | -9.4% | -4.6% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
The 50 largest of 132 share positions ($199,865,864) reported by Pavaki Capital Management LLC on Form 13F for the quarter ended Sep 30, 2026, filed Oct 26, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Nvidia Corporation14.85%
- Chevron Corporation10.52%
- Intuit5.32%
- Barrick MNG Corp4.61%
- Qualcomm Inc4.51%
- Regeneron Pharmaceuticals4.29%
- Milestone Pharmaceuticals In4.04%
- Textron Inc3.46%
- B2gold Corp3.08%
- Arcutis Biotherapeutics Inc2.47%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Nvidia Corporation | $29,689,400 | 14.85% | 130,000 | +400.00% |
| Chevron Corporation | $21,033,630 | 10.52% | 103,000 | +6.19% |
| Intuit | $10,642,406 | 5.32% | 38,600 | Unchanged |
| Barrick MNG Corp | $9,211,165 | 4.61% | 226,500 | +2.26% |
| Qualcomm Inc | $9,017,960 | 4.51% | 49,000 | Unchanged |
| Regeneron Pharmaceuticals | $8,568,451 | 4.29% | 11,300 | +14.14% |
| Milestone Pharmaceuticals In | $8,083,775 | 4.04% | 9,337,848 | +2.98% |
| Textron Inc | $6,918,960 | 3.46% | 90,800 | +7.71% |
| B2gold Corp | $6,159,952 | 3.08% | 1,180,000 | Unchanged |
| Arcutis Biotherapeutics Inc | $4,942,410 | 2.47% | 187,000 | Unchanged |
| Micron Technology Inc | $4,260,440 | 2.13% | 4,000 | Unchanged |
| Centerra Gold Inc | $3,856,123 | 1.93% | 177,000 | -10.15% |
| Newmont Corp | $3,748,550 | 1.88% | 32,500 | Unchanged |
| Ligand Pharmaceuticals Inc | $3,467,307 | 1.73% | 11,100 | Unchanged |
| SLB Limited | $2,971,920 | 1.49% | 61,000 | Unchanged |
| Harmony Biosciences Hldgs In | $2,865,980 | 1.43% | 73,000 | Unchanged |
| Ars Pharmaceuticals Inc | $2,842,876 | 1.42% | 659,600 | -24.13% |
| Royalty Pharma PLC | $2,567,840 | 1.28% | 44,000 | Unchanged |
| Bio Rad Labs Inc | $2,266,260 | 1.13% | 6,000 | Unchanged |
| Paramount Skydance Corp | $2,157,561 | 1.08% | 208,863 | Unchanged |
| Ishares Inc | $1,995,600 | 1.00% | 60,000 | Unchanged |
| FS KKR Cap Corp | $1,979,299 | 0.99% | 180,100 | +12.49% |
| SSR Mining In | $1,766,254 | 0.88% | 53,000 | -29.33% |
| Newamsterdam Pharma Company | $1,619,712 | 0.81% | 66,600 | Unchanged |
| Douglas Elliman Inc | $1,554,279 | 0.78% | 1,022,552 | Unchanged |
| Halliburton Co | $1,462,800 | 0.73% | 46,000 | Unchanged |
| Ishares TR | $1,318,920 | 0.66% | 58,000 | Unchanged |
| Yum China Hldgs Inc | $1,233,000 | 0.62% | 30,000 | Unchanged |
| Kinross Gold Corp | $1,192,698 | 0.60% | 49,500 | Unchanged |
| Baidu Inc | $1,129,310 | 0.56% | 13,000 | Unchanged |
| Syndax Pharmaceuticals Inc | $1,128,000 | 0.56% | 60,000 | Unchanged |
| Oceanagold Corp | $1,106,950 | 0.55% | 40,200 | Unchanged |
| Equinox Gold Corp | $1,010,790 | 0.51% | 91,000 | -9.00% |
| RMR Group Inc | $1,003,440 | 0.50% | 55,500 | +56.34% |
| Banco Bradesco S A | $930,463 | 0.47% | 264,336 | Unchanged |
| Ubs Group AG | $915,933 | 0.46% | 19,000 | Unchanged |
| Telefonaktiebolaget LM Erics | $892,125 | 0.45% | 97,500 | Unchanged |
| Royal Gold Inc | $885,000 | 0.44% | 3,750 | Unchanged |
| Orasure Technologies Inc | $858,609 | 0.43% | 219,033 | Unchanged |
| Icon Pub LTD Co | $849,950 | 0.43% | 5,000 | Unchanged |
| Sanofi SA | $824,600 | 0.41% | 20,000 | Unchanged |
| Baker Hughes Company | $823,500 | 0.41% | 15,000 | Unchanged |
| Kaspi KZ JSC | $818,322 | 0.41% | 8,700 | Unchanged |
| Biogen Inc | $790,580 | 0.40% | 3,500 | Unchanged |
| Merck & Co Inc | $726,550 | 0.36% | 5,000 | Unchanged |
| Lantheus Hldgs Inc | $706,663 | 0.35% | 7,100 | Unchanged |
| KBR Inc | $703,200 | 0.35% | 20,000 | Unchanged |
| Itau Unibanco Hldg S A | $702,872 | 0.35% | 82,400 | Unchanged |
| Cellebrite Di LTD | $675,600 | 0.34% | 60,000 | Unchanged |
| Diversified Healthcare TR | $667,250 | 0.33% | 85,000 | Unchanged |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 9 new positions, 9 sold out, 9 increased, 5 reduced and 109 unchanged.
Number of positions (a count, not dollars)
- New positions9
- Increased9
- Unchanged109
- Reduced5
- Sold out9
New positions
| Stock | Value | Shares |
|---|---|---|
| Caris Life Sciences Inc | $612,600 | 20,000 |
| Real Remax Group Inc | $210,635 | 12,875 |
| Huntington Ingalls Inds Inc | $186,949 | 700 |
| Nuvectis Pharma Inc | $158,400 | 7,500 |
| Honeywell Aerospace Inc | $154,970 | 1,000 |
| Genelux Corporation | $151,800 | 60,000 |
| Odyssey Therapeutics Inc | $111,100 | 5,000 |
| Eikon Therapeutics Inc | $80,400 | 10,000 |
| Wave Life Sciences Inc. | $55,500 | 15,000 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Advanced Micro Devices Inc | $2,323,640 | 4,000 |
| Nokia Corp | $929,600 | 70,000 |
| Replimune Group Inc | $890,028 | 80,400 |
| Intel Corp | $558,520 | 4,000 |
| Aris Mining Corporation | $447,300 | 30,000 |
| Catalyst Pharmaceuticals Inc | $251,440 | 8,000 |
| Re/max Hldgs Inc | $246,500 | 25,000 |
| Pebblebrook Hotel TR | $232,920 | 12,000 |
| Wave Life Sciences LTD | $87,150 | 15,000 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Nvidia Corporation | +104,000 | +400.00% | $29,689,400 | 130,000 |
| Chevron Corporation | +6,000 | +6.19% | $21,033,630 | 103,000 |
| Regeneron Pharmaceuticals | +1,400 | +14.14% | $8,568,451 | 11,300 |
| Textron Inc | +6,500 | +7.71% | $6,918,960 | 90,800 |
| RMR Group Inc | +20,000 | +56.34% | $1,003,440 | 55,500 |
| Milestone Pharmaceuticals In | +270,000 | +2.98% | $8,083,775 | 9,337,848 |
| FS KKR Cap Corp | +20,000 | +12.49% | $1,979,299 | 180,100 |
| Barrick MNG Corp | +5,000 | +2.26% | $9,211,165 | 226,500 |
| Novo-nordisk A S | +5,000 | +111.11% | $360,145 | 9,500 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Ars Pharmaceuticals Inc | -209,800 | -24.13% | $2,842,876 | 659,600 |
| SSR Mining In | -22,000 | -29.33% | $1,766,254 | 53,000 |
| Centerra Gold Inc | -20,000 | -10.15% | $3,856,123 | 177,000 |
| Silvercorp Metals Inc | -30,000 | -60.00% | $213,400 | 20,000 |
| Equinox Gold Corp | -9,000 | -9.00% | $1,010,790 | 91,000 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| Milestone Pharmaceuticals Inc. | 13G | 7.3% | 9,067,848 | Aug 7, 2026 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Aug 7, 2026, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.
Hedge funds filing Form D (1)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (1)
As reported in the adviser's Form ADV filed Mar 4, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures